TCE和CAR-T细胞在相似的NHL患者群体中具有类似的疗效*YESCARTA1 AXI-cel KYMRIAH2 Tisa-cel LUNSUMIO3 Mosunetuzumab Target/modality CD19 CAR T CD19 CAR T CD20 TCE(IV)Study/pt POP Zuma-5阶段2 R/R FL 3L+GO29781阶段2 R/R FL 3L+GO29781阶段2 R/R FL 3L+ORR/CR(%)91/60 86/68 80/60 MDOR(月)里程碑(如果可用)在12个月时无法评估76%在12个月时74%在12个月时不可评估71%在12个月时不可评估在12个月时不可评估72%在12个月时不可评估2.FDA包插入；Fowler等人；3.FDA包插入。*尚未进行面对面研究Mosunetuzumab(TCE)在经过大量预治疗的滤泡性淋巴瘤患者中获得了类似于CAR-T细胞的结果，具有现成的便利性，不需要淋巴耗竭化疗。

CLN-978：一种新型的CD19T细胞结合器，旨在提供T细胞定向效力和现成的便利性CLN-978在体外和体内有效地触发表达CD19的靶细胞的重定向裂解，以实现与CD19的非常高的亲和力结合，以有效地靶向表达很低CD19水平的B细胞CD3与CD19的相对结合亲和力比率被选为最佳治疗指标与血清白蛋白结合以延长血清半衰期，使每周皮下给药1 2 3 4CD19表达的B细胞1CLN-978𝛼-hSA(Vhh)𝛼-CD19(ScFv)𝛼-CD3(ScFv)3 4

与CD20或BCMA干细胞Pro-B细胞相比，靶向CD19实现了更广泛的B细胞室的覆盖1 BCMA-B细胞前B细胞未成熟的B细胞成熟的B细胞记忆B细胞浆细胞CD19 CD20 BCMA CD19定向治疗为深度和广泛的B细胞耗竭提供了巨大的潜力，因为这是免疫系统重置所必需的CD20不在浆细胞上表达，主要负责产生自身抗体的细胞1 BCMA指导的治疗耗尽长寿命的浆细胞并与严重感染的显著发生率有关2 1 Tedder，T.F.&Engel，P.CD20：B淋巴细胞的细胞周期进程的调节器。免疫系统。今天15,450-454(1994)。2雷诺兹等人。血液进步2023年

CLN-978临床前亮点：皮下给药实现快速、深度和持续的B细胞耗竭在NHPS中0.1 mg/kg(IV)1 mg/kg(IV)0.1 mg/kg(SC)1 mg/kg(SC)在NHPS中单剂皮下给药后深度、持续的外周B细胞耗竭在NHPS中NHP=非人灵长类动物的细胞因子释放减弱

骨髓脾淋巴组织GALT腋窝载体下颌骨CD20+细胞百分比CD20+细胞SC=皮下给药，GALT=肠道相关淋巴组织CLN-978对食蟹猴骨髓、脾和淋巴组织中B细胞的深度消耗15 10：5：0 60 40 20：0 80 60 40 20：0

B-NHL研究的临床观察(截至2024年4月5日)CLN-978在B-NHL中的临床观察：起始剂量临床活跃，具有良好的安全性疾病特征和疗效观察治疗紧急不良事件1 ID诊断先行治疗最佳反应持续时间(切森2014)非血液性血液病CRS ICANS 1 DLBCL 3 9剂量PD GR 1疲劳，注射部位反应，间歇性头痛Gr 4淋巴细胞减少2 Gr 1(发热)无2滤泡性3 24小时剂量(持续)SD Gr 1瘙痒Gr 4淋巴细胞减少Gr 1(发热)无3外套3 7剂CR Gr 3血管通路并发症(DVT)3，4 Gr 2间歇性躁动4 Gr 3淋巴细胞减少无1每类最高级别事件；2暂时性(

研究对象#3病例研究：68岁左侧下颌及邻近肌肉的外套细胞淋巴瘤7.4x1.7厘米肿块在基线体检中可触及调查者报告在第一剂CLN-978注射后96小时不再有肿块的检查在7剂CLN-978与完全代谢反应基线PET-CT一致后96小时重复PET-CT

服用CLN-978后，B-NHL患者表现出快速、深度和持续的B细胞耗竭。在2名B细胞处于基线水平的受试者中，2人表现出快速、深度和持续的B细胞耗竭。所有患者在开始剂量水平为每周30微克SC的治疗时，TBNK流量分析数据截止2024年3月20日最后一剂CLN978受试者1

CLN-978-SLE-001计划研究设计目标主要目标：CLN-978治疗活动期SLE的安全性次级目标：PKB细胞动力学免疫原性初步疗效A部分：剂量递增B部分：剂量扩展计划设计特点逐步递增以确定进一步开发的目标剂量纳入递增剂量以将细胞因子释放综合征的风险降至最低和神经毒性标准前用药包括皮质类固醇类药物住院监测48小时计划设计特点探索2种或更多给药方案在更多的SLE患者中研究人群SLE患者下列一种或多种自身抗体：抗核小体抗-dsDNA抗史密斯SLEDAI-2K≥8无中枢神经系统疾病指数计划提交3Q：24

系统性红斑狼疮(SLE)1：高未满足需求创造了一个引人注目的市场机会高未满足需求以B细胞产生的自身抗体为特征的系统性疾病，导致多个受影响的器官系统(肾脏、中枢神经系统、心血管、呼吸系统、皮肤)主要影响年轻、有色人种妇女约40%的SLE患者患上狼疮肾炎6，其10年死亡率为30%。目前的护理标准不会常规地导致无需治疗的缓解大多数患者需要终身免疫抑制，在不改变病程的情况下治疗症状包括狼疮性肾炎(LN)抗核抗体(ANA)阳性而不接受中枢神经系统(CNS)治疗的患者全球数据2023年估计-包括接受免疫抑制剂和/或生物制剂治疗的中、重度患者，如Benlysta(Belimumab)、Saphnelo Saphnelo Of(Anifrom Lumab)和Rituxan(Rituximab)的内部估计，基于诊断的中/重度患者总数(18-70岁/月)。公司文件-包括Benlysta(Belimumab)和Saphnelo(Anifrom Lumab)的收入。Mahajan，A.等人。狼疮。2020年8月；29(9)：1011-1020。122,000名可寻址患者2 163,000名确诊患者(18-70岁)美国SLE市场机会-2024年估计~85,000名正在接受现有治疗的中/重度患者3~15亿美元美国2023年现有治疗收入估计为110亿美元+估计中/重度变革性治疗机会4

大量可解决的自身免疫性疾病解决多种B细胞介导的自身免疫性疾病的机会50万+美国患者50,000-500,000美国患者

CLN-978计划：总结和下一步CLN-978的开发重新专注于自身免疫性疾病CD19是治疗自身免疫性疾病的最佳靶点CLN-978代表着潜在的一流机会，具有以下不同的好处：现成的便利性和皮下注射；潜在的疾病修改治疗，具有差异化的安全特征；灵活的方式，允许B-NHL患者根据需要重复给药，CLN-978的起始剂量，已经证明：深度和持续的B细胞耗竭临床活动包括在临床活跃剂量水平下对良好的安全性描述的完全反应SLE是计划于2024年第三季度提交IND的第一个适应症CLN-978有可能满足高度未满足的需求，并推动作为一种广泛的自身免疫性疾病的疾病修改治疗的显著价值[ZIPALERTINIB(CLN-081/TAS6417)EGFRex20ins抑制剂]外显子20插入的患者构成了带有EGFR突变的肺癌人群中最大的未满足需求部分。美国肺癌发病率1：238,340 NSCLC 1：80%-85%外显子202-4：1.5%-2.0%NSCLC~2,800-4,000患者其他13-20%Ex19缺失44%L858R 31%EX20~5%-12%参考文献1.美国癌症学会(2023)2.Riess JW等。J·托拉克·奥科尔。2018年；13(10)：1560-1568。DOI：10.1016/j.jtho.2018.06.019.3.张玉玲等人。目标是。2016年；7(48)：78985-78993。DOI：10.18632/oncoTarget.12587.4.Burnett H，et al.PLOS一号。2021；16(3)：e0247620。DOI：10.1371/Joural.pone.0247620.EGFR突变的非小细胞肺癌美国外显子20发病率

Zipert tinib(CLN-081/TAS6417)：对外显子20突变的非小细胞肺癌患者具有最佳潜力的选择性EGFR抑制剂ZIPALERTINIB：独特的设计特性独特的化学支架HER2-Sparing对突变型和WT EGFR的高选择性41%确认的总应答率(16/39)12个月中位数无进展生存可接受的安全性和耐受性描述来自PH 1/2A研究@100 MG BID状态更新2023年8月启动的一线第三阶段研究2022年第二季度进入共同开发/共同商业化美国监管里程碑2.75亿美元+1.3亿美元保留美国50%的利润份额2022年第四季度关键阶段2b研究在二线+启动2022年1月获得突破性治疗称号

齐帕替尼：在1/2a期试验中观察到100 mg BID剂量水平的卓越安全性和有效性

REZILIENT计划：与TAHO肿瘤学REZILIENT33 ClinicalTrials.gov合作，在多项研究和适应症中开发齐帕替尼，包括两项关键试验。政府网站的识别符：1NCT04036682、2NCT05967689和3NCT05973773；*包括已批准的和正在研究的外显子20疗法**遵循6-12名患者的安全性指引。PACC=P-环路和αC-螺旋齐帕尔替尼+培美曲塞+卡铂或顺铂安慰剂+培美曲塞+卡铂或顺铂主要终点：PFS R1：1N=~300**REZILIENT11化疗前+批准EX20治疗REZILNT22第一线EX20(齐帕尔替尼单一疗法)活性脑MET(+/-先前治疗)非外显子20不常见(PACC+)EGFRm(先前系统治疗)主要终点：ORR主要终点：ORR枢轴期2b队列(2022年第四季度启动)并行第二阶段1L随机第三阶段(2023年第三季度启动)

多样化的流水线利用新技术和差异化机制Programmodality/MOA Ind-Enabling第1阶段2阶段3状态Zipert tinib(CLN-081/TAS6417)EGFRex20ins抑制剂CLN-049 FLT3xCD3 T细胞结合蛋白CLN-619抗MICA/B抗体CLN-978 CD19xCD3 T细胞结合蛋白CLN-617胶原结合IL-12和IL-2融合蛋白NSCLC与外显子20插入突变2+线R/R AML，MDS泛癌系统性红斑狼疮-癌症关键阶段2b 2L+研究由YE24登记；第三阶段1L研究积极招募初始数据和单一治疗更新；疾病特异性扩展数据25上半年正在进行的第一阶段研究的临床更新24第二季度提交IND预计第三季度第一阶段研究正在进行的CLN-418 B7H4x41BB双特异性免疫激活剂多实体肿瘤早期计划持有美国联合开发/商业化权利与地理权拥有美国权利具有外显子20插入突变的NSCLC一线或其子公司拥有全球权利或其子公司拥有全球权利拥有全球权利或其子公司拥有全球权利2H24正在进行的第一阶段研究的临床最新情况

CD19 CAR-T cell therapy generated immune system reset and durable, treatment-free remissions in autoimmune patients Immune system reset: selected SLE PD data Muller, F. et al. NEJM 2024. 1) SLE = Systemic Lupus Erythematosus, IIM = idiopathic inflammatory myositis, SSc = systemic sclerosis Treatment free remissions in 3 autoimmune disease settings Mueller et al. (2024) treated 15 autoimmune patients (SLE, IIM, & SSc)1 with autologous CD19 CAR T SLE and IIM patients had complete resolution of disease symptoms; SSc patients reduced severity of skin and lung disease All patients successfully stopped immunosuppressive medication without having relapses or worsening disease Supported by deep B cell depletion, followed by immune reset and sustained diminution of autoantibodies Sustained drug-free remission are highly unlikely to be induced by lymphodepletion alone (e.g., some pts w/ prior chemotherapy) Observations SLE patients (n=8) SLEDAI-2K IIM patients (n=3) ACR-EULAR Total Improvement Score EUSTAR-AI Score SSc patients (n=4)

CAR T cell therapy: Promising outcomes but multiple challenges may limit broad uptake in autoimmune diseases Cell therapy limitations Available cellular therapies all require lymphodepleting chemotherapy, which has been associated with increased risk for infection, infertility, and secondary malignancies FDA has mandated boxed warnings across approved products highlighting the risk for secondary malignancies related to the CAR T cell therapy itself Complex manufacturing processes can introduce treatment delays for patients Reimbursement challenges continue to limit provider uptake for existing indications Treatment limited to specialized centers certified to provide CAR T cell therapies Prohibitive logistical and economic challenges will likely prevent retreatment upon relapse

TCE and CAR-T cells have comparable efficacy in similar NHL patient populations* YESCARTA1 Axi-cel KYMRIAH2 Tisa-cel LUNSUMIO3 Mosunetuzumab Target/Modality CD19 CAR T CD19 CAR T CD20 TCE (IV) Study / pt pop ZUMA-5 Phase 2  R/R FL 3L+ ELARA Phase 3 R/R FL 3L+ GO29781 Phase 2 R/R FL 3L+ ORR / CR (%) 91 / 60 86 / 68 80 / 60 mDOR (months) Landmarks (if available) Not evaluable 76% at 12 mo 74% at 18 mo Not evaluable 71% at 12 mo 22.8 mo 62% at 12 mo 57% at 18 mo FDA package insert.; 2. FDA package insert; Fowler et al; 3. FDA package insert.   * head-to –head studies have not been conducted Mosunetuzumab (TCE) achieves similar outcomes to CAR-T cells in heavily pre-treated follicular lymphoma patients with off-the-shelf convenience and no need for lymphodepleting chemotherapy.

CLN-978: A novel CD19 T cell engager designed to deliver T cell directed potency with off-the-shelf convenience CLN-978 potently triggers redirected lysis of CD19-expressing target cells in vitro and in vivo Engineered to achieve very high affinity binding to CD19 to efficiently target B cells expressing very low CD19 levels CD3 vs CD19 relative binding affinity ratio selected for optimal therapeutic index Binding to serum albumin for extension of serum half-life, enabling weekly subcutaneous dosing 1 2 3 4 CD19 expressing B-cell 1 CLN-978 𝛼-HSA (VHH) 𝛼-CD19 (scFv) 𝛼-CD3 (scFv) 3 2 4

Targeting CD19 achieves broader coverage of the B cell compartment compared to CD20 or BCMA Stem cell Pro-B cell Pre-B cell Immature B cell Mature B cell Memory B Cell Plasmablast Plasma cell CD19 CD20 BCMA CD19 directed therapies afford significant potential for deep and broad B cell depletion as is necessary for an immune system reset CD20 is not expressed on plasma cells, the cells primarily responsible for autoantibody production1 BCMA-directed therapies deplete long-lived plasma cells and have been associated with significant rates of severe infection2 1 Tedder, T. F. & Engel, P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol. Today 15, 450–454 (1994). 2 Reynolds et al. Blood Advances 2023

CLN-978 pre-clinical highlights: Subcutaneous dosing achieved rapid, deep and sustained B cell depletion with attenuated cytokine release in NHPs 0.1 mg/kg (IV) 1 mg/kg (IV) 0.1 mg/kg (SC) 1 mg/kg (SC) Deep, sustained peripheral B cell depletion after a single dose in NHPs Subcutaneous dosing attenuated cytokine release in NHPs NHPs = nonhuman primates

Bone marrow Spleen Lymphoid tissue GALT Axillary Vehicle Mandibular 0.1 mg/kg 1 mg/kg Percent CD20+ cells Percent CD20+ cells SC = subcutaneous administration, GALT = gut associated lymphoid tissue Deep B cell depletion in bone marrow, spleen and lymphoid tissues following SC administration of CLN-978 in cynomolgus monkeys 15 10  5  0 60 40 20  0 80 60 40 20  0 Percent CD20+ cells Bone Marrow Spleen Lymphoid Tissues

Clinical observations from B-NHL study (as of 5 April 2024) CLN-978 in B-NHL: Clinically active at starting dose with favorable safety Disease Characteristics and Efficacy Observations Treatment Emergent Adverse Events1 ID Diagnosis Prior Lines Duration of  CLN-978 Treatment Best Response (Cheson 2014) Non-Hematological Hematological CRS ICANS 1 DLBCL 3 9 doses PD Gr 1 fatigue, injection site reaction, intermittent headaches Gr 4 lymphopenia2 Gr 1 (fever) None 2 Follicular 3 24 doses (ongoing) SD Gr 1 pruritus Gr 4 lymphopenia Gr 1 (fever) None 3 Mantle 3 7 doses CR Gr 3 vascular access complication (DVT)3,4 Gr 2 intermittent restlessness4 Gr 3 lymphopenia None None 1Highest grade events reported per category; 2Transient (

Subject #3 case study: 68-year-old patient with mantle cell lymphoma 7.4 x 1.7 cm mass in left mandible and adjacent musculature was palpable on physical exam at baseline Investigator reported mass was no longer appreciated on exam 96 hours following the first dose of CLN-978 Repeat PET-CT after 7 doses of CLN-978 consistent with complete metabolic response Baseline PET-CT After 7 doses of CLN-978

Rapid, deep and sustained B cell depletion was demonstrated in B-NHL patients following CLN-978 dosing Rapid, deep and sustained B cell depletion was demonstrated in 2 of 2 subjects with measurable B cells at baseline All patients treated at the starting dose level of 30 ug SC weekly Peripheral blood TBNK flow assay Data cut-off 20 March 2024 Last dose CLN978 Subject 1

CLN-978-SLE-001 planned study design Objectives Primary Objective: Safety of CLN-978 for treatment of active SLE Secondary Objectives: PK B cell kinetics Immunogenicity Preliminary efficacy PART A: DOSE ESCALATION PART B: DOSE EXPANSION PLANNED DESIGN FEATURES Step-wise escalation to determine target dose for further development Incorporation of step-up dosing to minimize risk for cytokine release syndrome and neurotoxicity Standard pre-medication including corticosteroids In-patient monitoring for 48 hours PLANNED DESIGN FEATURES Exploration of 2 or more dosing schedules in a larger number of SLE patients Study Population SLE patients One or more of the following SLE autoantibodies: anti-nucleosome anti-dsDNA anti-Smith SLEDAI-2K ≥ 8 No CNS disease IND submission planned 3Q:24

Systemic Lupus Erythematosus (SLE)1: High Unmet Need Creates a Compelling Market Opportunity High Unmet Need Systemic disease characterized by autoantibodies produced by B cells, leading to multiple affected organ systems (renal, CNS, cardiovascular, respiratory, skin) Largely impacts young, women of color ~40% of SLE patients develop Lupus Nephritis6, which has a 10-year 30% mortality rate  Current standards of care do not routinely induce treatment-free remission Most patients require lifelong immune suppression, treating symptoms without modifying course of disease Includes Lupus Nephritis (LN) Antinuclear Antibody (ANA) positive without Central Nervous System (CNS) treated patients Global Data 2023 Estimate – includes moderate or severe patients treated with immunosuppressive agents and or biologic agents, such as Benlysta (belimumab), Saphnelo (anifrolumab) and Rituxan (rituximab) Internal estimates based on total diagnosed moderate/severe patient population (18-70 y/o). Company filings – includes revenue for Benlysta (belimumab) and Saphnelo (anifrolumab). Mahajan, A. et al. Lupus. 2020 Aug; 29(9): 1011–1020. 122,000 Addressable patients2 163,000 Diagnosed patients (18-70 y/o) U.S. SLE Market Opportunity – 2024 Estimate ~85,000 Estimated moderate/severe patients on available therapies3 ~$1.5b Estimated U.S. 2023 revenue from currently available therapies5 $11b+ Estimated moderate/severe opportunity with transformative therapies4

Substantial number of addressable autoimmune diseases Opportunity to Address Multiple B Cell Mediated Autoimmune Diseases 500,000+ U.S. Patients 50,000 - 500,000 U.S. Patients

CLN-978 program:  Summary and next steps CLN-978 development refocused exclusively on autoimmune diseases  CD19 is the optimal target for autoimmune diseases CLN-978 represents a potential first in class opportunity with the following differentiated benefits:  Off-the-shelf convenience and subcutaneous delivery  Potential disease-modifying treatment with a differentiated safety profile  Flexible modality allowing for repeat dosing as needed In B-NHL patients, CLN-978 at the starting dose, has demonstrated:  Rapid, deep and sustained B cell depletion  Clinical activity including a complete response  Favorable safety profile at a clinically active dose level SLE is the first indication with an IND submission planned for 3Q 2024 CLN-978 has the potential to address high unmet need and drive significant value as a disease-modifying treatment across a broad range of autoimmune diseases

ZIPALERTINIB(CLN-081/TAS6417) EGFRex20ins inhibitor

Patients with insertions at exon 20 make up the largest unmet need segment of the lung cancer population with EGFR mutations U.S. Lung cancer incidence1: 238,340 NSCLC1: 80%-85% Exon 202-4: 1.5%-2.0% of NSCLC~2,800-4,000 patients Other 13-20% Ex19Deletion 44% L858R 31% Ex20 ~5%-12% References 1. American Cancer Society (2023) 2. Riess JW, et al. J Thorac Oncol. 2018;13(10):1560-1568. doi:10.1016/j.jtho.2018.06.019. 3. Zhang YL, et al. Oncotarget. 2016;7(48):78985-78993. doi:10.18632/oncotarget.12587. 4. Burnett H, et al. PLoS ONE. 2021;16(3):e0247620. doi:10.1371/journal.pone.0247620. EGFR MUTATED NSCLC U.S. EXON 20 INCIDENCE

Zipalertinib (CLN-081/TAS6417): Selective EGFR inhibitor with best-in-class potential for NSCLC patients with exon20 mutations ZIPALERTINIB: UNIQUE DESIGN PROPERTIES Distinct chemical scaffold HER2-sparing High selectivity to mutant vs WT EGFR 41%confirmed overall rate of response (16/39) 12-monthmedian progression-free survival Favorablesafety and tolerability profile KEY DATA FROM PH 1/2A STUDY @ 100 MG BID STATUS UPDATE AUG 2023 Pivotal Phase 3 study in frontline initiated Q2 2022 Entered into co-development / co-commercialization with Taiho Oncology, $275M upfront + $130M in U.S. regulatory milestones, retaining 50% of U.S. profit share Q4 2022 Pivotal Phase 2b study in second line+ initiated JAN 2022 Granted Breakthrough Therapy Designation

Zipalertinib: Superior safety and efficacy observed at 100mg BID dose level in Phase 1/2a trial

REZILIENT program: zipalertinib development across multiple studies and indications, including 2 pivotal trials, in collaboration with Taiho Oncology REZILIENT33 Clinicaltrials.gov identifiers: 1NCT04036682, 2NCT05967689 and 3NCT05973773; * includes both approved and investigational exon20 therapies ** following 6-12 patient safety lead in. PACC = P-loop and αC-helix Zipalertinib + pemetrexed + carboplatin or cisplatin Placebo + pemetrexed + carboplatin or cisplatin Primary endpoint: PFS R1:1N=~300** REZILIENT11 Prior chemo only Prior chemo + approved ex20 treatment REZILIENT22 1st Line ex20 (zipalertinib monotherapy) Active brain mets (+/- prior treatment) Non-exon20ins uncommon (PACC+) EGFRm (prior systemic therapy) Primary endpoint: ORR Primary endpoint: ORR Pivotal Phase 2b cohorts (initiated Q4 2022) Key Parallel Phase 2 cohorts 1L Randomized Phase 3 (initiated Q3 2023)

Diversified pipeline leveraging novel technologies and differentiated mechanisms ProgramModality/MOA IND-Enabling Phase 1 Phase 2 Phase 3 Status Zipalertinib(CLN-081/TAS6417) EGFRex20ins inhibitor CLN-049 FLT3xCD3 T-cell engager CLN-619 Anti-MICA/B antibody CLN-978 CD19xCD3 T-cell engager CLN-617 Collagen-binding IL-12 and IL-2fusion protein NSCLC with exon 20 insertion mutations 2+ line R/R AML, MDS Pan-cancer Systemic lupus erythematosus Pan-cancer Pivotal Phase 2b 2L+ study enrolled by YE24; Phase 3 1L study actively enrolling Initial combo data and monotherapy update in 2Q24; Disease specific expansion data in 1H25 Clinical update from ongoing Phase 1 study in 2H24 IND submission expected in 3Q24 Phase 1 study ongoing CLN-418 B7H4x41BB bispecific immune activator Multiple solid tumors Early Programs holds US co-development/-commercialization rights with Geographic Rights owns U.S. rights NSCLC with exon 20 insertion mutations frontline or its subsidiaryowns worldwide rights or its subsidiaryowns worldwide rights owns worldwide rights or its subsidiaryowns worldwide rights Clinical update from ongoing Phase 1 study in 2H24